Summary of treatment-related adverse events
| Adverse events | All grades, n (%) | Grade 1, n (%) | Grade 2, n (%) | Grades 3–4, n (%) |
|---|---|---|---|---|
| Fatigue | 4 (15.38) | 3 (11.54) | 1 (3.85) | 0 (0) |
| Anorexia | 2 (7.69) | 0 (0) | 2 (7.69) | 0 (0) |
| Weight loss | 1 (3.85) | 1 (3.85) | 0 (0) | 0 (0) |
| Pharyngalgia | 3 (11.54) | 3 (11.54) | 0 (0) | 0 (0) |
| Mucositis oral | 1 (3.85) | 1 (3.85) | 0 (0) | 0 (0) |
| Cough | 2 (7.69) | 2 (7.69) | 0 (0) | 0 (0) |
| Hand-foot syndrome | 6 (23.08) | 5 (19.23) | 0 (0) | 1 (3.85) |
| Urinary tract infection | 1 (3.85) | 0 (0) | 1 (3.85) | 0 (0) |
| Hematuria | 2 (7.69) | 2 (7.69) | 0 (0) | 0 (0) |
| Proteinuria | 4 (15.38) | 4 (15.38) | 0 (0) | 0 (0) |
| Hypertension | 15 (57.69) | 4 (15.38) | 4 (15.38) | 7 (26.92) |
| TSH elevation | 9 (34.62) | 9 (34.62) | 0 (0) | 0 (0) |
| Hypothyroidism | 2 (7.69) | 2 (7.69) | 0 (0) | 0 (0) |
| Hypertriglyceridemia | 1 (3.85) | 1 (3.85) | 0 (0) | 0 (0) |
| Hypercholesterolemia | 1 (3.85) | 1 (3.85) | 0 (0) | 0 (0) |
| LDL elevation | 2 (7.69) | 2 (7.69) | 0 (0) | 0 (0) |
| Alanine aminotransferase | 2 (7.69) | 1 (3.85) | 1 (3.85) | 0 (0) |
| Aspartate aminotransferase | 1 (3.85) | 0 (0) | 1 (3.85) | 0 (0) |
LDL, low-density lipoprotein; TSH, thyroid-stimulating hormone.